Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

Core Insights - Contineum Therapeutics, Inc. announced positive topline data from its PIPE-791 Phase 1b PET trial, achieving its primary objectives [1] Company Overview - Contineum Therapeutics is a clinical-stage biopharmaceutical company focused on developing differentiated therapies for neuroscience, inflammation, and immunology indications [1]